Dealing in securities
Johannesburg, Friday, 02 October 2020. Following the announcement on 30 September 2020 of the resignation of directors and in compliance with paragraphs 3.63 to 3.74 of the JSE Listings Requirements, the following information is disclosed:
A. VESTING IN SHARE APPRECIATION RIGHTS AND SALE OF ORDINARY SHARES BY DIRECTOR PRIOR TO RESIGNATION
The following transactions are disclosed in relation to SARS:
| 1.Name of director: | F Abbott |
| Nature of transaction: | The off-market issuance of shares to settle SARS |
| Date of vesting of SARS issued in 2014: | 17 November 2019 |
| Number of 2014 SARS vested to date: | 21 208 |
| 2014 SARS issue value per share: | R18.41 |
| 1-day Volume Weighted Average price of shares | R87.60 |
| Nature of transaction: | On market sale of shares |
| Number of ordinary shares issued to settle 2014 SARS: | 16 751 |
| Date of sale: | 29 September 2020 |
| Selling price per share: | R91.42 |
| Day highest sale price: | R93.41 |
| Day lowest sale price: | R89.33 |
| Proceeds for total on market sale: | R1 531 376.42 |
| Class of Securities: | Ordinary Shares |
| Nature and extent of prescribed officer’s interest:; | Direct beneficial |
Prior clearance was obtained in respect of the above dealings by the director.
For more details contact:
Marian van der Walt
Senior Group Executive: Enterprise Risk and Investor Relations
+27(0)82 888 1242 (mobile)
Max Manoeli
Senior Investor Relations Coordinator
+27(0)82 759 1775 (mobile)
Johannesburg, South Africa
2 October 2020
Sponsor:
J.P. Morgan Equities South Africa Proprietary Limited